Interim 18F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine |
| |
Authors: | Jae-Cheol?Jo,Dok?Hyun?Yoon,Shin?Kim,Kyoungmin?Lee,Eun?Hee?Kang,Jung?Sun?Park,Jin-Sook?Ryu,Jooryung?Huh,Chan-Sik?Park,Jong?Hoon?Kim,Sang?Wook?Lee,Cheolwon?Suh author-information" > author-information__contact u-icon-before" > mailto:csuh@amc.seoul.kr" title=" csuh@amc.seoul.kr" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author |
| |
Affiliation: | 1.Department of Oncology, Asan Medical Center,University of Ulsan College of Medicine,Seoul,South Korea;2.Department of Nuclear Medicine,University of Ulsan College of Medicine,Ulsan,South Korea;3.Department of Pathology,University of Ulsan College of Medicine,Ulsan,South Korea;4.Department of Neurosurgery,University of Ulsan College of Medicine,Ulsan,South Korea;5.Department of Radiation Oncology, Asan Medical Center,University of Ulsan College of Medicine,Seoul,South Korea;6.Department of Hematology and Oncology, Ulsan University Hospital,University of Ulsan College of Medicine,Ulsan,South Korea |
| |
Abstract: | 18F-fluoro-2-dexoy-D-glucose-positron emission tomography (PET)/computed tomography (CT) is a useful imaging technique for monitoring the treatment response in lymphoma cases. We investigated the value of interim brain PET/CT (I-PET/CT) for monitoring the response to intensive methotrexate-based chemotherapy in primary central nervous system lymphoma (PCNSL) patients with diffuse large B cell lymphoma (DLBCL). Of the 76 PCNSL patients treated with intensive methotrexate and cytarabine chemotherapy between September 2006 and December 2012, 66 patients with DLBCL were included in this study. The patient cohort of 66 individuals comprised 43 men and 23 women with a median age of 59 years (range, 17–75 years). During chemotherapy, 36 patients (54.5%) showed a negative metabolism on I-PET/CT, and 47 (71.2%) were negative on final (F) PET/CT. The baseline characteristics were similar between I-PET/CT-negative (n = 36) and I-PET/CT-positive patients (n = 30) except ECOG performance status. After a median follow-up of 27.5 months, there was no difference in the progression-free survival (PFS; P = 0.701) or overall survival (OS; P = 0.620) between the I-PET/CT-negative and I-PET/CT-positive groups. However, PFS in the F-PET/CT-negative group was significantly longer than that in the F-PET/CT-positive group (P < 0.001) without a significant difference in OS (P = 0.892). I-PET/CT may not predict the survival outcome of PCNSL patients with DLBCL treated with intensive methotrexate and cytarabine chemotherapy. Prospective trials are required to fully evaluate the role of I-PET/CT. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|